Purpose of the development: For the treatment and prevention of cardiovascular diseases, it allows to intensify the endogenous synthesis tiamindifosfata, improve the cardiovascular system.

Recommended application field: Medicine.

Advantages over analogues: In therapeutic properties of the drug "KARDIOVIT" surpasses its closest analogue "kokarboksilaz" has better permeability across cell membranes, eliminates partial or complete phosphorylation.

The development stage readiness: Ready for application

Description of the development:
()
The drug "KARDIOVIT" contains four components, which act synergistically to narrow links of cellular metabolism. The drug "KARDIOVIT" activates cellular metabolism in such a way that: - increases the efficiency of use of not only two vitamins (B1 and E), which are part of the drug, but also other endogenous vitamins contained in the tissues; - increases the absorption of vitamins from food due to activation of the transport systems; - increases the level of reduced glutathione in the tissue; - reduces the synthesis and accumulation of fat.

Information about newness of the development:
there are Ukrainian patents -- 1 items

corresponds technical description
Ready for implementation

Possibility of transfer abroad:
Licence's sale

Photo

Country Ukraine

For additional information turn to:
E-mail: gal@uintei.kiev.ua